- Claritas (KLY) has initiated a second development program with R-107, the company’s proprietary nitric oxide-releasing compound
- R-107, the company’s proprietary nitric oxide-releasing compound, is being developed as a nasal spray
- The R-107 nasal spray is designed to increase the level of nitric oxide present in the nasal cavities to kill invading viruses, including COVID-19
- Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
- Claritas Pharmaceuticals, Inc. (KLY) is down 9.09 per cent, trading at C$0.05 per share at 12 pm EST
Claritas Pharmaceuticals, Inc. (KLY) has initiated a second development program with R-107, the company’s proprietary nitric oxide-releasing compound.
Claritas is currently developing R-107 as a therapy for vaccine-resistant COVID-19, influenza and other viral infections.
The additional program will develop R-107 as a nasal spray designed to be used prophylactically to prevent viral infections.
Hundreds of peer-reviewed publications have documented that naturally occurring nitric oxide in the nasal cavities is a primary defence against invading viruses.
Nasal nitric oxide prevents and reduces the rate and severity of various viral infections, including viruses responsible for the flu, the common cold and COVID-19.
When a viral threat has entered cells in the nasal cavities, the body’s white blood cells engulf the virus and release a burst of nitric oxide to destroy it. However, in cases of fulminating, or rapidly replicating viruses, the viral load can overwhelm the ability of naturally occurring nitric oxide to eliminate the virus.
The R-107 nasal spray that Claritas is developing is designed to increase the level of nitric oxide present in the nasal cavities to kill the invading viruses, thereby reducing the rate, severity and spread of viral infections.
The company believes that its R-107 nasal spray could potentially be used as a preventative measure to reduce the rate and severity of the symptoms of COVID-19 or as an early intervention to prevent viral infection from spreading beyond the nasal cavities.
Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada.
Claritas Pharmaceuticals, Inc. (KLY) is down 9.09 per cent, trading at C$0.05 per share at 12 pm EST.
